ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
 > Asthma Allergy News
Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
New Treatment for Anthrax Approved
FDA cites preparedness for intentional release of deadly bacteria

WEDNESDAY, March 25, 2015 (HealthDay News) -- A new treatment to prepare the United States for the potential release of deadly inhalational anthrax has been approved by the U.S. Food and Drug Administration.

Anthrasil (Anthrax Immune Globulin Intravenous) is sanctioned, when combined with approved antibiotics, to support the nation's preparedness against a possible anthrax attack, the FDA said Wednesday in a news release. Other rare but possible means of human exposure to the deadly bacteria include infected animals or contaminated animal products.

Anthrasil is made from the plasma of people who have been vaccinated against anthrax. The plasma includes antibodies that neutralize poisons produced by anthrax, the FDA said. The drug will be stored in the U.S. Strategic National Stockpile for use in an "anthrax emergency," the agency said.

Because it wasn't "feasible or ethical" to expose people to anthrax, Anthrasil's effectiveness was tested in rabbits and monkeys, the agency said. The vaccine's safety was evaluated among 74 healthy people who weren't exposed to anthrax. The most common side effects included headache, back pain, nausea, pain at the injection site and swelling.

Anthrasil is produced by Cangene Corp., based in Winnipeg, Canada.

More information

Visit the FDA to learn more.



-- Scott Roberts

Copyright © 2015 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS